Protagonist Therapeutics (PTGX) opened 2026 with Q1 revenue of US$56.4 million, Basic EPS of US$0.06 and net income of US$3.8 million, while trailing 12 month figures show revenue of US$74.1 million, a Basic EPS loss of US$1.79 and a net loss of US$114.7 million. Over the past year, the company has seen quarterly revenue move between US$4.7 million and US$170.6 million, alongside Basic EPS that has ranged from a US$2.11 profit to a US$0.69 loss. These figures give investors a broad set of reference points for how the current quarter compares with recent history. With revenue in the tens of millions and margins still shaped by loss-making trailing results, this update focuses attention on how efficiently Protagonist Therapeutics is translating its pipeline progress into sustainable profitability.

See our full analysis for Protagonist Therapeutics.

With the headline numbers in place, the next step is to consider how this earnings profile aligns with the prevailing growth and risk narratives that have developed around Protagonist Therapeutics over the last year.

US$56 million top line sits against US$74 million trailing revenue base

• Q1 2026 revenue of US$56.4 million sits within a trailing 12 month revenue total of US$74.1 million, which means most of the recent revenue base is concentrated in a handful of quarters rather than spread evenly across the year.
• What stands out for a bullish view that focuses on growth is that trailing 12 month revenue is reported as growing at 27.6% per year, yet the latest quarter’s US$56.4 million sits well below past quarters like Q4 2024 at US$170.6 million, so anyone leaning bullish on revenue momentum needs to reconcile that headline growth rate with the uneven quarterly pattern.

Curious how this kind of uneven revenue profile feeds into different long term storylines around PTGX, including both growth hopes and loss focused concerns, and how other investors are framing it right now? Curious how numbers become stories that shape markets? Explore Community Narratives

From US$114.7 million trailing loss to a US$3.8 million quarterly profit

• Over the trailing 12 months Protagonist Therapeutics recorded a net loss of US$114.7 million, yet Q1 2026 on its own shows a net income of US$3.8 million and positive Basic EPS of US$0.06 after several recent quarters with Basic EPS between a US$0.55 loss and a US$0.69 loss.
• Supporters with a bullish stance who point to losses shrinking at about 31.6% per year over five years get some backing from this, because the move from quarterly net losses like US$44.4 million in Q4 2025 to a quarterly profit of US$3.8 million lines up with that longer term loss reduction trend, even though the trailing 12 month line is still firmly in loss territory.

DCF fair value of US$379.45 versus US$103.97 share price

• The stock trades at US$103.97 while the provided DCF fair value is US$379.45 and the P/B of 10.2x sits well above the US Biotechs industry average of 2.3x but below the peer group at 23.6x, so valuation signals pull in different directions.
• Critics taking a bearish angle often point to the current unprofitability on a trailing 12 month basis and the higher P/B versus the broader industry, and those points are grounded in the US$114.7 million trailing loss and 10.2x P/B, yet the same data set also shows the stock trading roughly 72.6% below the DCF fair value and paired with forecast earnings growth of 42.59% per year, which creates a clear tension between multiple based caution and model based upside in the valuation debate.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Protagonist Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

After reading this, do you feel the story leans more optimistic or cautious? Take a closer look at the numbers, compare them with your own expectations, and decide whether the balance of risks and potential rewards fits your approach, then check the 2 key rewards.

See What Else Is Out There

Protagonist Therapeutics combines a trailing 12 month loss of US$114.7 million with uneven revenue and profitability that may leave you questioning the risk profile.

If that kind of volatility makes you uneasy, it is worth urgently checking out 74 resilient stocks with low risk scores so you can focus on companies with more resilient financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.